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Resistance to antibiotics is increasing dangerously worldwide
[1,2]. Methicillin-resistant Staphylococcus aureus and vancomy-
cin-resistant enterococci have been spreading for many
years, explaining the massive usage of vancomycin. Enterobac-
teriaceae harbouring extended spectrum b-lactamases (ESBL)
have spread more recently, but quickly [3,4]. We have not
been reactive enough with ESBL because it was evident that
carbapenems would be the next target [5,6]. This class of
drugs, which represents our last line of therapy, is needed
not only to treat severe and nosocomial infections, but also,
in several countries, to treat community-acquired infections.
Resistance to this class of drug will increase rapidly, leaving
us with almost nothing except the old, sometimes toxic,
drugs that have been almost forgotten. There are numerous
mechanisms for resistance to carbapenems [6], which can
easily spread worldwide (e.g. KPC, OXA 48, NDM-1).
NDM-1 recently received much media coverage because it
was found in British people returning from India [7]. The
way in which people live and travel today, massive immigra-
tion and troop mobilization all accelerate the spread of
multi-resistant bacteria [8]. The screening of possible carri-
ers, with the application of the Dutch ‘search and destroy’
strategy is difﬁcult to establish on a large scale. Micro-organ-
isms resistant to almost every antibiotic are already present
in many countries, requiring the use of the old ‘toxic’ anti-
biotics, such as colistin. There are huge differences between
countries, and Scandinavian countries, the Netherlands and
Switzerland still have low levels of both methicillin-resistant
Staphylococcus aureus and resistant Gram-negative bacteria.
Resistance is not new, but we were ‘saved’ until recently by
the regular introduction of new effective compounds, belong-
ing to many different classes. This time, the pipeline is almost
dry for drugs active against Gram-negative bacteria. There
are a reasonable number of recent, effective compounds that
are active against Gram-positive cocci, but no new antibacte-
rial agent active against Gram-negative bacteria is expected
in the next few years. Therefore, for Gram-negative bacteria,
we are back 30 years, and the risk of large epidemic out-
breaks, leading to a true pandemic with multi-resistant bacte-
ria, is real. This is something of a return for bacteria, after a
long period of viral supremacy. What are the causes of this
dramatic situation? In most countries, people still use too
many antibiotics, empirically, in particular to treat viral infec-
tions, such as pharyngitis, or bronchitis or urinary coloniza-
tion, often without using the available and simple diagnostic
tests. To treat severe infections, and for the sake of their
patient, prescribers use broad-spectrum antibiotics to pre-
vent treatment failures, but seldom re-evaluate this initial
therapy, nor do they de-escalate treatment, even when it
would be safe for the patients. Treatments are still far too
long. In several countries, access to antibiotics is free, in the
pharmacies, or over-the-counter. The problem is also dra-
matic in animals. A recent study, performed in the
Netherlands shows that up to 80% of hens harbour ESBL
Gram-negative bacteria [9]. Antibiotic consumption in ani-
mals worldwide is excessive, although huge differences are
noted between European countries [10]. The Netherlands
and France are the highest consumers.
At the same time, companies have de-invested the ﬁeld of
antibiotic therapy, which is considered to have a high cost
and risk : beneﬁt ratio, and a limited market for drugs
because of their low price. Resistance increases sharply, and
no new antibiotic appears on the horizon—a deadly duo!
Life, in the community and in hospitals is a succession of
small or large and silent epidemic outbreaks with both sus-
ceptible and resistant micro-organisms. Infection control
measures are still applied, but in most countries in a subopti-
mal way, and screening of carriers remains difﬁcult and far
too costly for most countries. So it is difﬁcult to prevent the
spread of a new mechanism of resistance, for example ESBL.
Can we survive without antibiotics? A large international
meeting was organized in 2011 in France, by Biome´rieux,
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with the title Ready for a world without antibiotics? The answer
was obviously ‘NO’, or not at present. Antibiotics remain
the key actor in the management of infections.
Can we survive with only a few old antibiotics? In this
issue of Clinical Microbiology and Infection, three antibiotics
are re-visited: colistin, co-trimoxazole and fosfomycin. The
review by Raz [11] underlines the increased role of fosfomy-
cin as a therapeutic option against multidrug-resistant
pathogens, particularly those responsible for urinary tract
infections. For co-trimoxazole, Goldberg and Bishara [12]
summarize the accumulated evidence in the literature on the
new, ‘unconventional’ clinical use of co-trimoxazole during
the last three decades. Obviously, those compounds are still
effective against both Gram-positive and Gram-negative
organisms. Colistin remains efﬁcient even for Gram-negative
bacteria that harbour carbapenemases, or complex associ-
ated mechanisms, such as Pseudomonas aeruginosa. It is less
toxic than anticipated. However, more strains are becoming
resistant to colistin. Yahav et al. [13] in their review summa-
rize the results of studies on the clinical use of colistin
administered intravenously or as an aerosol. The article of
Couet et al. [14] conducts a critical review with prospective
thoughts and focuses on the most recent pharmacokinetic
studies on colistin, published during the last few years or
months, or not yet published but only presented at interna-
tional meetings. Combination therapy (mandatory for fosfo-
mycin administered intravenously) is often used to increase
the efﬁciency of these three drugs, and limit the occurrence
of resistance. However, the best partner remains to be
determined even if aminoglycosides are often used when a
combination of colistin and fosfomycin would be a reason-
able therapy for infections caused by resistant Gram-negative
bacteria.
It is important, sociologically, to better understand why
people do not seem to be frightened by the problem of anti-
biotic resistance, although it could represent the next pan-
demic! It is not clear why such huge amounts of energy and
resources have been put into the preparedness for H1N1
‘micro-pandemia’, and why it is so difﬁcult to motivate politi-
cians or healthcare organizations, such as WHO, on anti-
biotic resistance, and to urgently set up a strong and
coordinated programme, with precise and pragmatic actions.
Probably people think that new antibiotics will appear, as
happened in the past. It is time to react vigorously to pro-
tect and save antibiotics, and to try to stop the continuing
spiral of resistance. For this to happen, a strong cooperation
between healthcare professionals, in both human and animal
medicine, and consumers is needed, and simple, but powerful
and convincing, information must be given to the politicians
and the public.
Some groups have been active for many years, trying to
promote these actions. We could cite ReAct—Action on
Antibiotic Resistance and APUA, the Alliance for the Prudent
Use of Antibiotics, which were created in 1981. We created
recently a World Alliance against Multi-resistant Bacteria
[15]. Three hundred and twenty professionals, from many
horizons in human and animal medicine support this alliance,
as well as 35 medical specialties or professional bodies
(including large European societies). Sixty-ﬁve well-known
international experts constitute our international scientiﬁc
advisory committee. More importantly, consumers (Le Lien,
Le Collectif Interassociatif Sur la Sante´) are fully involved in
this alliance, and it is hoped that consumers from countries
other than France will join. The Alliance proposes a com-
bined programme, including four mandatory and simulta-
neous actions: the upgrade of infection control measures;
the spread of antibiotic stewardship programmes, with active
protection of antibiotics; the use and development of diag-
nostic tests; and the acceleration and facilitation of research
and access to new antibiotics. Together, we can reach a
positive outcome, and help to save antibiotics.
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